Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.22.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS

 

                                         
                COVID-19              
    Breast Cancer Test     Alzheimer     Testing and related products     Un-allocated     Total  
    Unaudited  
Three months ended March 31, 2022                              
Revenues     -       -       2,199       -       2,199  
Operating loss     (1,107 )     -       (1,303 )     (1,707 )     (4,117 )
Unallocated amounts:                                                     
Financing expenses, net                             (3,471 )     (3,471 )
Share in losses of affiliated companies accounted for under equity method, net                             -       -  
Net loss     (1,107 )     -       (1,303 )     (5,178 )     (7,588 )
SUMMARY OF REVENUES BY GEOGRAPHIC REGION

 

                 
   

Three months period ended

March 31,

 
    2022     2021  
    Unaudited  
Israel   $ -     $ -  
United States     2,199       5,031  
Total     2,199       5,031  

 

 

TODOS MEDICAL LTD.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

(U.S. dollars in thousands)

 

D. Property and equipment, net, by geographic areas:

 

                 
    As of March 31,     As of December 31,  
    2022     2021  
    Unaudited  
Israel   $ 31     $ 34  
United States     2,082       2,011  
Property and equipment, net   $ 2,113     $ 2,045  
SCHEDULE OF MAJOR CUSTOMER

 

                 
    As of March 31,  
    2022     2021  
Client A     -       85.3 %
Client B     27.2 %     -  
                 
Client D     11.2 %     -  
Total     38.4 %     85.3 %